Grumabix (Abiraterone Acetate)

Grumabix is indicated for the treatment of metastatic castration‑resistant prostate cancer (mCRPC) in patients who have previously received androgen‑deprivation therapy.

• Used in combination with prednisone to improve overall survival.
• Prescribed for patients whose disease has progressed despite standard hormonal therapy.
• Considered when androgen synthesis needs to be further suppressed.
• May be part of a treatment regimen after chemotherapy failure.
• Administered orally to provide systemic inhibition of CYP17A1.

The safety profile of Grumabix includes a range of adverse events that vary in frequency and severity.

Common

• Fatigue or decreased energy levels that may affect daily activities.
• Joint or muscle pain, often described as aching or stiffness.
• Elevated liver enzymes detected in routine blood tests, indicating hepatic stress.
• Fluid retention leading to peripheral edema, particularly swelling of the ankles and feet.

Serious

• Severe hypertension or sudden spikes in blood pressure that may require immediate medical attention.
• Clinically significant liver toxicity, including jaundice, hepatitis, or hepatic failure.
• Signs of adrenal insufficiency such as persistent nausea, vomiting, abdominal pain, or dangerously low blood pressure.

Before initiating Grumabix, clinicians should evaluate several patient‑specific factors and monitor for potential risks during therapy.

• Assess liver function tests; Grumabix may exacerbate hepatic impairment.
• Monitor blood pressure regularly because the drug can cause hypertension.
• Evaluate for cardiovascular disease, as fluid retention may worsen heart failure.
• Screen for adrenal insufficiency; concomitant glucocorticoid replacement is often required.
• Review concomitant medications that affect CYP17 or steroid metabolism.
• Counsel patients on the importance of adhering to prescribed prednisone dosing to mitigate steroid‑related side effects.

Grumabix can interact with other medicines that influence steroid metabolism, blood pressure, or liver function, requiring careful management.

Avoid

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) that may increase abiraterone exposure.
• Medications that cause significant hypertension, such as certain decongestants or stimulants.
• Drugs with known hepatotoxic potential, including high‑dose acetaminophen.
• Concomitant use of strong CYP2D6 inhibitors, which may alter steroid metabolism.

Use with caution

• Anticoagulants, as fluid retention may affect bleeding risk.
• Antihypertensive agents, as dose adjustments may be needed to control blood pressure.
• Other hormonal therapies, which could compound endocrine side effects.
• Lithium therapy, as electrolyte shifts from fluid changes may affect lithium levels.